UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 21.486

Sortiert nach

Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer

Business Wire, 2024-06-03

2024

Link zum Volltext

Verfügbarkeit prüfen

Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer

Business Wire, 2024-06-03

2024

Link zum Volltext

Verfügbarkeit prüfen

Tolmar Announces Results From Inaugural Landmark Survey of US Physicians To Assess Current State of Testosterone Replacement Therapy (TRT) and the Impact on Practices and Patient Care

PR newswire, 2024-06-02

2024

Link zum Volltext

Verfügbarkeit prüfen

EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024

Business Wire, 2024-05-31

2024

Link zum Volltext

Verfügbarkeit prüfen

Gilead Provides Update on Phase 3 TROPiCS-04 Study

Business Wire, 2024-05-30

2024

Link zum Volltext

Verfügbarkeit prüfen

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Business Wire, 2024-05-29

2024

Link zum Volltext

Verfügbarkeit prüfen

FDA Grants Priority Review to Merck's Application for KEYTRUDA (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Business Wire, 2024-05-29

2024

Link zum Volltext

Verfügbarkeit prüfen

AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024

PR newswire, 2024-05-28

2024

Link zum Volltext

Verfügbarkeit prüfen

Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival

Business Wire, 2024-05-28

2024

Link zum Volltext

Verfügbarkeit prüfen

Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)

Business Wire, 2024-05-28

2024

Link zum Volltext

Verfügbarkeit prüfen

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant at the ASCO 2024 Annual Meeting

PR newswire, 2024-05-24

2024

Link zum Volltext

Verfügbarkeit prüfen

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting

PR newswire, 2024-05-24

2024

Link zum Volltext

Verfügbarkeit prüfen

BRUKINSA Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL

Business Wire, 2024-05-24

2024

Link zum Volltext

Verfügbarkeit prüfen

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant at the ASCO 2024 Annual Meeting

Business Wire, 2024-05-23

2024

Link zum Volltext

Verfügbarkeit prüfen

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting

Business Wire, 2024-05-23

2024

Link zum Volltext

Verfügbarkeit prüfen

Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

PR newswire, 2024-05-23

2024

Link zum Volltext

Verfügbarkeit prüfen

Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

Business Wire, 2024-05-21

2024

Link zum Volltext

Verfügbarkeit prüfen

Bayer presents latest data from oncology portfolio at 2024 ASCO Annual Meeting

Business Wire, 2024-05-16

2024

Link zum Volltext

Verfügbarkeit prüfen

FDA APPROVES IMDELLTRA(TM) (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

PR newswire, 2024-05-16

2024

Link zum Volltext

Verfügbarkeit prüfen

Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma

Business Wire, 2024-05-13

2024

Link zum Volltext

Verfügbarkeit prüfen

Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial

Business Wire, 2024-05-10

2024

Link zum Volltext

Verfügbarkeit prüfen

Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent

Business Wire, 2024-05-09

2024

Link zum Volltext

Verfügbarkeit prüfen

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

Business Wire, 2024-05-06

2024

Link zum Volltext

Verfügbarkeit prüfen

European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite

Business Wire, 2024-05-06

2024

Link zum Volltext

Verfügbarkeit prüfen

European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo for the First-Line Treatment of Adult Patients with Microsatellite

Business Wire, 2024-05-06

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 21.486

Suche als RSS-Feed

Aktive Filter

PublikationsformArtikel

PublikationsformNewsletter-Artikel

PublikationsformBerichte

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(275)
Mit Volltextzugriff
(5.699)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

7 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

ProQuest Dissertations & Theses A&I
(12.599)
Ebook Central Perpetual and DDA
(6.413)
eBooks on EBSCOhost
(6.077)
Nexis Uni
(1.826)
ScienceDirect eBooks
(1.462)
Wiley Online Library All Obooks
(1.168)
Taylor & Francis eBooks A-Z
(1.049)
HEAL-Link subscriptions: Springer Book Series
(226)
Ingenta
(158)
MEDLINE
(130)
EZB Electronic Journals Library
(78)
Single Journals
(58)
EBSCOhost Business Source Ultimate
(51)
De Gruyter eBooks
(34)
WK Lippincott Williams & Wilkins–Connect here FIRST to enable access
(24)
SAGE Complete
(21)
Elsevier ScienceDirect Journals Complete
(17)
IngentaConnect Journals
(13)
JSTOR
(13)
Wiley Online Library
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Business Wire
(916)
Pr Newswire
(611)
Monthly Prescribing Reference
(247)
Drug Topics
(23)
M2 Presswire
(15)
The Lancet
(10)
Mlo. Medical Laboratory Observer
(8)
Journal Of Diagnostic Medical Sonography
(7)
The Clinical Advisor
(7)
Good Housekeeping
(6)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(195)
... seit 90 Tagen
(363)

Menü

Weitere Dienste

Einstellungen

Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer

Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer

Tolmar Announces Results From Inaugural Landmark Survey of US Physicians To Assess Current State of Testosterone Replacement Therapy (TRT) and the Impact on Practices and Patient Care

EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024

Gilead Provides Update on Phase 3 TROPiCS-04 Study

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

FDA Grants Priority Review to Merck's Application for KEYTRUDA (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024

Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival

Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant at the ASCO 2024 Annual Meeting

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting

BRUKINSA Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant at the ASCO 2024 Annual Meeting

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting

Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

Bayer presents latest data from oncology portfolio at 2024 ASCO Annual Meeting

FDA APPROVES IMDELLTRA(TM) (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma

Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial

Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite

European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo for the First-Line Treatment of Adult Patients with Microsatellite

Aktive Filter

Suchergebnisse filtern